Table 2.
Univariate and multivariate Cox regression analyses of OS of nonsmall cell lung carcinoma patients
| Variables | N | Univariate Cox | Multivariate Cox | ||||
|---|---|---|---|---|---|---|---|
| (40853) | HR | 95% CI | P value | HR | 95% CI | P value | |
| Age | |||||||
| <60 | 10909 (26.7) | 1 | – | – | 1 | – | – |
| 60–70 | 14758 (36.1) | 1.275 | 1.222–1.329 | <0.001 | 1.328 | 1.273–1.386 | <0.001 |
| >70 | 15186 (37.1) | 1.779 | 1.710–1.852 | <0.001 | 1.924 | 1.847–2.006 | <0.001 |
| Sex | |||||||
| Female | 21170 (51.8) | 1 | – | – | 1 | – | – |
| Male | 19683 (48.2) | 1.522 | 1.476–1.569 | < 0.001 | 1.361 | 1.319–1.404 | 0.052 |
| Race | |||||||
| White | 33903 (82.98) | 1 | – | – | |||
| Black | 3729 (9.12) | 0.965 | 0.915–1.018 | 0.189 | |||
| Others | 3221 (7.88) | 0.773 | 0.726–0.823 | < 0.001 | |||
| Assistant treatment | |||||||
| Neither | 22767 (55.729) | 1 | – | – | 1 | – | – |
| Radiotherapy | 1081 (2.64) | 2.397 | 2.215–2.595 | <0.001 | 1.54 | 1.421–1.67 | <0.001 |
| Chemotherapy | 2225 (5.44) | 1.290 | 1.241–1.341 | <0.001 | 0.82 | 0.784–0.857 | <0.001 |
| Both | 1045 (2.55) | 2.002 | 1.915–2.094 | <0.001 | 1.047 | 0.991–1.106 | 0.103 |
| Histological type | |||||||
| Adenocarcinoma | 22767 (55.729%) | 1 | – | – | 1 | – | – |
| Adenosquamous carcinoma | 1081 (2.64%) | 1.534 | 1.408–1.671 | <0.001 | 1.291 | 1.185–1.406 | <0.001 |
| Bronchi alveolar carcinoma | 2225 (5.44%) | 0.638 | 0.592–0.689 | <0.001 | 0.756 | 0.704–0.816 | <0.001 |
| Large cell carcinoma | 1045 (2.55%) | 1.625 | 1.495–1.767 | <0.001 | 1.589 | 1.461–1.728 | <0.001 |
| NSCLC (unspecified) | 1134 (2.77%) | 1.456 | 1.344–1.578 | <0.001 | 1.284 | 1.184–1.392 | <0.001 |
| Squamous cell carcinoma | 10632 (26.02%) | 1.461 | 1.411–1.512 | <0.001 | 1.228 | 1.185–1.273 | <0.001 |
| Other | 1969 (4.81%) | 0.876 | 0.808–0.948 | 0.001 | 0.909 | 0.839–0.985 | 0.02 |
| MLNR | |||||||
| 0 | 30628 (74.97%) | 1 | - | - | 1 | - | - |
| 0–0.31 | 6643 (16.26%) | 1.858 | 1.789–1.930 | <0.001 | 1.752 | 1.678–1.829 | <0.001 |
| ≥0.31 | 3582 (8.76%) | 2.698 | 2.581–2.820 | <0.001 | 2.52 | 2.399–2.648 | <0.001 |
| ELNs | |||||||
| <16 | 32819 (80.33%) | 1 | – | – | – | – | – |
| ≥16 | 8034 (19.67%) | 1.124 | 0.993–1.362 | 0.086 | – | ||
| AJCC 8th T stage | |||||||
| T1a | 1687 (4.13%) | 1 | – | – | 1 | – | – |
| T1b | 8744 (21.41%) | 1.297 | 1.163–1.446 | <0.001 | 1.214 | 1.088–1.353 | 0.001 |
| T1c | 6824 (16.70%) | 1.791 | 1.607–1.996 | <0.001 | 1.534 | 1.376–1.71 | <0.001 |
| T2a | 10567 (25.86%) | 2.149 | 1.934–2.389 | <0.001 | 1.769 | 1.591–1.967 | <0.001 |
| T2b | 3086 (7.53%) | 2.775 | 2.479–3.108 | <0.001 | 2.116 | 1.887–2.371 | <0.001 |
| T3 | 5837 (14.28%) | 3.121 | 2.803–3.476 | <0.001 | 2.389 | 2.142–2.664 | <0.001 |
| T4 | 4108 (10.06) | 3.748 | 3.362–4.179 | <0.001 | 2.864 | 2.563–3.199 | <0.001 |
AJCC, American Joint Committee on Cancer; CI, confidence interval; ELNs, examined lymph node numbers; HR, hazardous ratio; MLNR, metastatic lymph node ratio; NSCLC, nonsmall cell lung carcinoma; NSCLC (unspecified), nonsmall cell lung carcinoma (unspecified but not listed above); Other, other malignant tumors categories other than above and small cell lung cancer in SEER database.